New Treatments in Atopic Dermatitis

Price: FREE for members and non-members

Session recorded on June 22, 2022
Speaker: Luz Fonacier, MD

Viewers can earn credit by completing the posttest questions.

This program is a collaboration between the American College of Allergy, Asthma and Immunology and the Allergy and Asthma Network.

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Primary Care Providers
Fellows-in-Training

Learning Objectives

Upon completion of this activity learners should be able to:

  1. Discuss underlying pathophysiology of atopic dermatitis and targets of treatment
  2. Discuss use of assessment tools for Identifying patients with moderate to severe atopic dermatitis
  3. Discuss current and new treatment of moderate to severe AD
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines an “ineligible company” as companies whose primary business is producing, marketing, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include:

Ambulatory procedure centers

  • Blood banks
  • Diagnostic labs that do not sell proprietary products
  • Electronic health records companies
  • Government or military agencies
  • Group medical practices
  • Health law firms
  • Health profession membership organizations
  • Hospitals or healthcare delivery systems
  • Infusion centers
  • Insurance or managed care companies
  • Nursing homes
  • Pharmacies that do not manufacture proprietary compounds
  • Publishing or education companies
  • Rehabilitation centers
  • Schools of medicine or health science universities
  • Software or game developers

 

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified conflicts of interest have been mitigated

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
06/22/2022
Course expires: 
06/21/2023
Rating: 
5

There are many new treatment for AD that has been approved since Dec 2021 and allergists have to be familiar with many treatment options for this common and potentially debilitating disease.

All relevant finaicial relationships have been mitigated.

Michael Blaiss, MD, FACAAI Planner
Disclosures: Consultant: ALK, DBV, Hycor, Merck, Pfizer, Sanofi, Stallergenes Greer, PMD Healthcare

Luz Fonacier, MD, FACAAI Speaker
Disclosures:
 Advisor: Abbie, Lilly; Advisor, Indpendent Contractor: Regeneron; Advisor, Indpendent Contractor, Researcher: Pfizer

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Please login or create an account to take this course.